ADAR1 Capital Management LLC Has $3.04 Million Stake in Savara Inc (NASDAQ:SVRA)

ADAR1 Capital Management LLC raised its position in shares of Savara Inc (NASDAQ:SVRA) by 33.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 988,468 shares of the company’s stock after acquiring an additional 245,834 shares during the period. ADAR1 Capital Management LLC’s holdings in Savara were worth $3,035,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Cibc World Markets Corp purchased a new position in Savara during the fourth quarter valued at approximately $33,000. KLP Kapitalforvaltning AS purchased a new position in shares of Savara during the 4th quarter valued at $41,000. Virtu Financial LLC purchased a new position in shares of Savara during the 3rd quarter valued at $67,000. BNP Paribas Financial Markets increased its stake in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after acquiring an additional 4,732 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on SVRA. Wells Fargo & Company assumed coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Savara in a report on Friday, March 28th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $2.85 on Monday. The business’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $3.20. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 52 week low of $2.26 and a 52 week high of $5.34. The firm has a market cap of $492.00 million, a price-to-earnings ratio of -6.63 and a beta of 0.52.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. As a group, equities research analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.